Justification of a price range for topical antifungal drugs based on patient preferences
DOI:
https://doi.org/10.14739/2310-1210.2025.1.311194Keywords:
antifungal agents, pharmacoeconomics, willingness to pay, van Westendorp method, sociological survey, pharmaceutical provision, pharmaceutical assistanceAbstract
The price factor is an important element when using a therapy management, that is complicated by the deterioration in the socio-economic situation of Ukrainians and the National Health Care system in the middle of war.
The aim is to examine patients’ willingness-to-pay for topical antifungal drugs (TAFDs) taking into account their differing consumer characteristics in order to justify the economic component in the development and pharmaceutical market introduction of national drugs and to formulate recommendations for improving the level of pharmaceutical care for patients with fungal skin diseases.
Materials and methods. The results of a sociological TAFDs’ consumer survey were used as the basic study material. In this study, the methods of information retrieval, summarizing, formalizing, questioning, van Westendorp’s Price Sensitivity Meter (PSM) were used. The respondent geography covered the Zaporizhzhia, Dnipropetrovsk, Cherkasy, Poltava, Ivano-Frankivsk, Kyiv, Odesa regions.
Results. A total group analysis of price sensitivity was conducted including 8 TAFDs with calculation of optimal (OPP), indifferent (IDP), minimum (MCP) and maximum (MEP) respondents’ willingness-to-pay prices. The same prices were subsequently calculated in the intra-group price analysis of respondents with different income levels and experience in drug therapy for fungal skin diseases. The cumulative distribution of respondents was graphed at three stages of the study calculations for the identified subgroups (64 graphs in total).
Conclusions. The van Westendorp’s Price Sensitivity Meter (PSM) has been used to examine patients’ willingness-to-pay for topical antifungal drugs considering their different consumer characteristics: final dosage form – gel, ointment, cream, solution, spray; combined / monocomponent. At the same time, opinion of patients with different levels of income and experience of drug therapy for fungal skin diseases has been sought. Based on the studies, the economic component and the promising form of a new antifungal drug for topical use (pharmacy or industrial production) – a spray or gel with a price in the range of UAH 181–230 have been justified.
References
Kamwiziku GK, Makangara JC, Orefuwa E, Denning DW. Serious fungal diseases in Democratic Republic of Congo - Incidence and prevalence estimates. Mycoses. 2021;64(10):1159-69. doi: https://doi.org/10.1111/myc.13339
Lass-Flörl C, Steixner S. The changing epidemiology of fungal infections. Mol Aspects Med. 2023;94:101215. doi: https://doi.org/10.1016/j.mam.2023.101215. Epub 2023 Oct 5. Erratum in: Mol Aspects Med. 2024;95:101240. doi: https://doi.org/10.1016/j.mam.2023.101240
Fisher MC, Alastruey-Izquierdo A, Berman J, Bicanic T, Bignell EM, Bowyer P, et al. Tackling the emerging threat of antifungal resistance to human health. Nat Rev Microbiol. 2022;20(9):557-1. doi: https://doi.org/10.1038/s41579-022-00720-1
Albahar F, Alhamad H, Abu Assab M, Abu-Farha R, Alawi L, Khaleel S. The Impact of Antifungal Stewardship on Clinical and Performance Measures: A Global Systematic Review. Trop Med Infect Dis. 2023;9(1):8. doi: https://doi.org/10.3390/tropicalmed9010008
Logan C, Martin-Loeches I, Bicanic T. Invasive candidiasis in critical care: challenges and future directions. Intensive Care Med. 2020;46(11):2001-14. doi: https://doi.org/10.1007/s00134-020-06240-x
United Nations. Goal 3: Ensure healthy lives and promote well-being for all at all ages [Internet]. United Nations Sustainable Development Goals. United Nations; 2024. Available from: https://www.un.org/sustainabledevelopment/health/
Asmamaw G, Shimelis T, Tewuhibo D, Bitew T, Ayenew W. Access to essential medicines used in the management of noncommunicable diseases in Southern Ethiopia: Analysis using WHO/HAI methodology. SAGE Open Med. 2024;12:20503121241266318. doi: https://doi.org/10.1177/20503121241266318
Kamphuis BW, Kanavos P. Assessing pricing and reimbursement policies for generic pharmaceuticals in the MENA region for improved efficiency, affordability and generic penetration. Health Policy Open. 2021;2:100045. doi: https://doi.org/10.1016/j.hpopen.2021.100045
Horgan D, Spanic T, Apostolidis K, Curigliano G, Chorostowska-Wynimko J, Dauben HP, et al. Towards Better Pharmaceutical Provision in Europe-Who Decides the Future? Healthcare (Basel). 2022;10(8):1594. doi: https://doi.org/10.3390/healthcare10081594
Bongomin F, Ekeng BE, Kwizera R, Salmanton-García J, Kibone W, van Rhijn N, et al. Fungal diseases in Africa: Closing the gaps in diagnosis and treatment through implementation research and advocacy. J Mycol Med. 2023;33(4):101438. doi: https://doi.org/10.1016/j.mycmed.2023.101438
Mahanova TV, Tkachenko NA, Popovych VP. A study to evaluate willingness to pay using Van Westendorp’s method on the example of contraceptives. J Appl Pharm Sci. 2022;12(05):178-86. doi: https://doi.org/10.7324/JAPS.2022.120516
Bidaud AL, Schwarz P, Herbreteau G, Dannaoui E. Techniques for the Assessment of In Vitro and In Vivo Antifungal Combinations. J Fungi (Basel). 2021;7(2):113. doi: https://doi.org/10.3390/jof7020113
Andersone A, Janceva S, Lauberte L, Ramata-Stunda A, Nikolajeva V, Zaharova N, et al. Anti-Inflammatory, Anti-Bacterial, and Anti-Fungal Activity of Oligomeric Proanthocyanidins and Extracts Obtained from Lignocellulosic Agricultural Waste. Molecules. 2023;28(2):863. doi: https://doi.org/10.3390/molecules28020863
Zhong H, Han L, Lu RY, Wang Y. Antifungal and Immunomodulatory Ingredients from Traditional Chinese Medicine. Antibiotics (Basel). 2022;12(1):48. doi: https://doi.org/10.3390/antibiotics12010048
Camaioni L, Ustyanowski B, Buisine M, Lambert D, Sendid B, Billamboz M, et al. Natural Compounds with Antifungal Properties against Candida albicans and Identification of Hinokitiol as a Promising Antifungal Drug. Antibiotics (Basel). 2023;12(11):1603. doi: https://doi.org/10.3390/antibiotics12111603
Downloads
Additional Files
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
